In the setting of TTP, the anti-VWF nanobody rapidly reversed the marked decline in platelet count, along with normalization of lactate dehydrogenase (LDH) levels (which correlates with VWF activity). This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.